MarketCap
Facebook
X
Telegram
QIAGEN N.V. General and Administrative Expenses | QGEN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 128 M | 112 M | 112 M | 141 M | 200 M | 129 M | 104 M | 127 M | 199 M | 152 M | 186 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 104 M | 145 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B |  USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
547 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
19.8 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
5.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
42.1 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
T2 Biosystems
TTOO
|
24.8 M | - | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Bioventus
BVS
|
314 M | $ 13.0 | 1.39 % | $ 866 M | USA |
 |
DarioHealth Corp.
DRIO
|
15.2 M | $ 6.75 | 2.31 % | $ 26.9 M | Israel |
 |
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
21.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Anixa Biosciences
ANIX
|
6.63 M | $ 2.69 | 1.45 % | $ 87.3 K | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
87.5 M | $ 27.7 | 1.09 % | $ 209 M | USA |
 |
BioNano Genomics
BNGO
|
35.2 M | $ 1.56 | 17.29 % | $ 8.49 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
126 M | $ 11.68 | 0.69 % | $ 123 M |  China |
 |
CareDx, Inc
CDNA
|
108 M | $ 52.64 | 0.52 % | $ 2.81 B | USA |
 |
Celcuity
CELC
|
27.2 M | $ 82.7 | 0.1 % | $ 3.87 B | USA |
 |
Co-Diagnostics
CODX
|
9.06 M | $ 1.14 | 2.7 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 272.88 | 0.59 % | $ 13.5 B | USA |
 |
Castle Biosciences
CSTL
|
229 M | $ 35.5 | 6.16 % | $ 1.03 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 247.08 | 3.9 % | $ 27.4 B | USA |
 |
Meridian Bioscience
VIVO
|
57.1 M | - | - | $ 1.49 B | USA |
 |
Biomerica
BMRA
|
3.23 M | $ 2.3 | 0.42 % | $ 6.7 M | USA |
 |
Fulgent Genetics
FLGT
|
117 M | $ 21.28 | 3.05 % | $ 655 M | USA |
 |
Guardant Health
GH
|
211 M | $ 175.65 | 4.65 % | $ 22 B | USA |
 |
ICON Public Limited Company
ICLR
|
780 M | $ 172.45 | 2.08 % | $ 13.5 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 510.73 | 0.23 % | $ 41.1 B | USA |
 |
Danaher Corporation
DHR
|
8.24 B | $ 209.36 | 3.01 % | $ 149 B | USA |
 |
Illumina
ILMN
|
1.09 B | $ 222.29 | 6.76 % | $ 34.5 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 269.67 | 1.51 % | $ 46.4 B | USA |
 |
Brainsway Ltd.
BWAY
|
5.8 M | $ 13.46 | 0.14 % | $ 457 M | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 323.97 | 2.75 % | $ 27 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 100.73 | 0.41 % | $ 6.8 B | USA |
 |
DexCom
DXCM
|
1.29 B | $ 86.45 | 2.09 % | $ 33.7 B | USA |
 |
Medpace Holdings
MEDP
|
198 M | $ 620.48 | 4.21 % | $ 17.9 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 330.4 | 3.47 % | $ 27.4 B | Schweiz |
 |
Myriad Genetics
MYGN
|
257 M | $ 3.88 | 2.37 % | $ 359 M | USA |
 |
ENDRA Life Sciences
NDRA
|
3.72 M | $ 5.66 | 1.13 % | $ 4.45 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 18.89 | 2.61 % | $ 2.42 B | USA |
 |
Neogen Corporation
NEOG
|
245 M | $ 12.25 | 2.51 % | $ 2.66 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 21.96 | 5.63 % | $ 492 M | USA |
 |
Natera
NTRA
|
1.18 B | $ 350.78 | 2.63 % | $ 48 B | USA |
 |
OPKO Health
OPK
|
223 M | $ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.34 | 0.37 % | $ 402 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
628 M | $ 24.9 | 1.99 % | $ 23.6 B |  Niderland |
 |
Personalis
PSNL
|
53.6 M | $ 16.1 | 0.31 % | $ 1.44 B | USA |